The HER2CLIMB-05 trial is a randomized, double blind, placebo-controlled, pivotal Phase 3 study evaluating the efficacy and safety of TUKYSA compared to placebo, both in combination with trastuzumab ...
NEW YORK-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 fourth-quarter 2026 dividend on the company’s common stock, payable December 7, 2026, ...
LITFULO significantly improved facial and total body repigmentation at Week 52 compared to placebo, with continuous improvement starting at Week 24, supporting planned regulatory filings for a ...
(NYSE: PFE) today presented detailed results from an ongoing Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate-t ...
Pfizer Inc. (NYSE: PFE) will present data from 45 company-sponsored, investigator-sponsored, and collaborative research abstracts at the European Society for Medical Oncology (ESMO) Congress, taking ...
Understand the types of multiple myeloma, signs and symptoms of the disease as well as common symptoms, risk factors, and current treatment options. Multiple myeloma is a type of cancer that forms in ...
Pfizer believes that privacy is a fundamental right. Personal data is at the core of scientific and medical innovation, and your personal health data can play a critical role in helping you and your ...
The 230-acre site in Sanford, North Carolina, just south of the famed Research Triangle, is home to one of the largest U.S. biotechnology hubs. The site has flexible, multi-product manufacturing ...
At Pfizer, we’re eager to connect with you. Follow Pfizer and our CEO Albert Bourla’s Influencer posts on LinkedIn and Twitter. Get your Pfizer news in small bits by following @Pfizer and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results